Efficacy of Dual Antiplatelet Therapy Combined with Naoxintong Capsules(脑心通胶囊) Following Coronary Mi

来源 :第四届全国中西医结合脑心同治学术交流会 | 被引量 : 0次 | 上传用户:hanqianggege
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: To evaluate the efficacy of dual antiplatelet therapy combined with Naoxintong Capsule (脑心通胶囊, NXTC) in a rat model of coronary mlcroembollzation (CME).Methods: A total of 95 rate were randomly divided into 6 groups: control, sham-operation, CME model, NXTC, dual antiplatelet (clopldogrel and aspirin) intervention (DA), and NXTC combined with DA (NDA) groups.The complete data in 69 rate were obtained.The number of CME, myocardial apoptosis rate, bleeding time, clotting time, and adensosine diphosphate (ADP)-induced platelet aggregation were assessed.Results: Compared with the CME group, the number of CME and myocardial apoptosis rates were significantly decreased in the NXTC, DA, and NDA groups (P<0.01).Compared with other intervention groups, the number of CME and myocardial apoptosis rates were the least in the NDA group (P<0.01), and the Incidence of surgical bleeding was the highest in the DA group (P<0.01).Compared with the CME group, ADP-induced maximum platelet aggregation rate was significantly inhibited in the NXTC, DA, and NDA groups (P<0.01), both bleeding time and clotting time were significantly increased in the NXTC, DA, and NDA groups (P<0.01), while the above parameters were the highest in the DA group (P<0.05).Condusion: The combination therapy of NXTC and DA enhanced the anti-CME effect of either therapy alone and reduced the risk of the DA therapy-associated bleeding, demonstrating an improved benefit/ risk ratio in the rat model of CME.
其他文献
目的:观察稳心颗粒治疗心脏神经症合并期前收缩的临床疗效.方法:将120例心脏神经症合并期前收缩患者随机分为治疗组和对照组各60例,两组在性别、年龄、病程、症状、心电图表现等诸方面无明显差异.治疗组采用稳心颗粒治疗,对照组采用谷维素治疗,每周随访1次,四周后进行1次临床症状全面评估和动态心电图复查.结果:治疗组临床症状改善总有效率90%,对照组67%;治疗组动态心电图期前收缩改变总有效率85%,对照
目的:观察中药丹红注射液对不稳定心绞痛(UAP)血瘀证患者PCI术后血管内皮的保护作用及其机制.方法:采用随机、对照的研究方法,设丹红治疗组和对照组,分别纳入50例接受PCI的UAP血瘀证患者,对照组给予常规治疗,丹红组于PCI术前1~3天接受常规药物治疗+丹红注射液(40mL,每天1次),术后继续应用4~6天(围术期共应用7天).于丹红给药前及末次给药次日分别不抗凝采血10mL,采用ELISA法
丹红注射液是一种草本的传统中药制剂,提取自丹参和红花.目前,在中国丹红注射液主要用于治疗心脏疾病患者.临床观察表明,丹红注射液可以提高患者血流量,减缓多种综合症.然而,丹红注射液能否抑制动脉粥样硬化及其所涉及的机制还没有完全阐明.在本研究中,我们使用了两个动脉粥样硬化动物模型即ApoE-/-和LDLR-/-小鼠,研究在两种模式鼠中丹红注射液对动脉粥样硬化发展的影响.我们将这两种小鼠各分为两组,分别
临床结果发现丹红注射液可以增加血液的流动,也可以减少心血管疾病病人的一些相关症状.然而,丹红注射液改善相关症状的机理仍不是很清楚,例如:丹红对于原发性腹主动脉瘤是否具有保护作用.在本论文中,我们假定丹红注射液能够抑制apoE敲除小鼠的腹主动脉瘤的发生.我们将30只apoE敲除小鼠随机分成2组,喂食高脂食物,并且分别注射生理盐水(每天100.1)或者丹红注射液(每天注射100.1),实验持续16周.
目的:研究丹红注射液对2型糖尿病模型鼠dh/db雄性小鼠由糖尿病引起的视网膜病变和肾病的治疗作用及其相关的作用机制。方法:我们选取了20只6周龄的雄性2型糖尿痛模型dh/db小鼠,随机平均分成2组:对照组和丹红注射液组,丹红组每天腹腔注射丹红注射液(5 ml/kg体重),对照组注射等量生理盐水;同时选取10只6周龄雄性C57BL/6野生小鼠作为正常指标对照。小鼠全部喂食正常食物,共处理12周。实验
目的:观察丹红注射液对脑缺血再灌注损伤大鼠和缺氧损伤神经元细胞的保护作用.方法:①成年雄性Wistar 大鼠随机分为模型组、假手术组、丹红注射液(0.9,1.8,3.6 mL·kg-1)组和阳性对照(依达拉奉,6mg·kg-1)组,采用线栓法制备大鼠大脑中动脉阻塞(middle cerebral artery occlusion,MCAO)模型,缺血60 min后再灌注72 h,分别于造模前30
会议
会议
会议